IN2014CN02153A - - Google Patents

Info

Publication number
IN2014CN02153A
IN2014CN02153A IN2153CHN2014A IN2014CN02153A IN 2014CN02153 A IN2014CN02153 A IN 2014CN02153A IN 2153CHN2014 A IN2153CHN2014 A IN 2153CHN2014A IN 2014CN02153 A IN2014CN02153 A IN 2014CN02153A
Authority
IN
India
Prior art keywords
scleral
corneal
pdt
chlorophyll
anomalies
Prior art date
Application number
Other languages
English (en)
Inventor
Avigdor Scherz
Yoram Salomon
Arie Marcovich
Alexander Brandis
Daniel Wagner
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of IN2014CN02153A publication Critical patent/IN2014CN02153A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N5/0613Apparatus adapted for a specific treatment
    • A61N5/062Photodynamic therapy, i.e. excitation of an agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/06Radiation therapy using light
    • A61N2005/0658Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659Radiation therapy using light characterised by the wavelength of light used infrared

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN2153CHN2014 2011-08-23 2012-08-23 IN2014CN02153A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161526414P 2011-08-23 2011-08-23
PCT/IL2012/050325 WO2013027222A1 (en) 2011-08-23 2012-08-23 (bacterio)chlorophyll photosensitizers for treatment of eye diseases and disorders

Publications (1)

Publication Number Publication Date
IN2014CN02153A true IN2014CN02153A (pt) 2015-05-29

Family

ID=46889394

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2153CHN2014 IN2014CN02153A (pt) 2011-08-23 2012-08-23

Country Status (20)

Country Link
US (4) US9452172B2 (pt)
EP (1) EP2747763B1 (pt)
JP (1) JP6215203B2 (pt)
KR (1) KR101962991B1 (pt)
CN (1) CN103930108B (pt)
AU (1) AU2012298156B2 (pt)
BR (1) BR112014004306A2 (pt)
CA (1) CA2846011C (pt)
CL (1) CL2014000432A1 (pt)
DK (1) DK2747763T3 (pt)
ES (1) ES2856698T3 (pt)
HK (1) HK1199412A1 (pt)
HU (1) HUE053321T2 (pt)
IN (1) IN2014CN02153A (pt)
MX (1) MX360683B (pt)
PE (1) PE20141183A1 (pt)
PT (1) PT2747763T (pt)
RU (1) RU2632439C2 (pt)
WO (1) WO2013027222A1 (pt)
ZA (1) ZA201402056B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9622911B2 (en) 2010-09-30 2017-04-18 Cxl Ophthalmics, Llc Ophthalmic treatment device, system, and method of use
EP2729180B1 (en) 2011-07-08 2019-01-23 The University of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
US9566301B2 (en) 2012-03-29 2017-02-14 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
EP2830627B1 (en) 2012-03-29 2024-05-01 Epion Therapeutics, Inc. Ocular treatment solutions, delivery devices and delivery augmentation methods
RU2635185C2 (ru) * 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
US11207410B2 (en) 2015-07-21 2021-12-28 Avedro, Inc. Systems and methods for treatments of an eye with a photosensitizer
CN106620893B (zh) * 2015-07-23 2021-07-30 爱博诺德(北京)医疗科技股份有限公司 用于眼部疾病光治疗的材料
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
CN105601638B (zh) * 2016-01-28 2018-10-26 东北林业大学 一种叶绿酸衍生物及其制备方法、作为光敏抑菌剂及光敏杀虫剂的应用
US10342697B2 (en) 2016-04-13 2019-07-09 Avedro, Inc. Systems and methods for delivering drugs to an eye
WO2017193019A1 (en) * 2016-05-05 2017-11-09 David Muller Corneal implant systems and methods
CN110167494A (zh) * 2017-01-03 2019-08-23 维特安公司 用于治疗视网膜脱离的方法和装置
US11826426B2 (en) 2017-08-02 2023-11-28 The University Of Chicago Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
CN109091685A (zh) * 2018-08-10 2018-12-28 北京市眼科研究所 一种对角膜炎提取细菌病原体的灭活方法
WO2020086691A1 (en) 2018-10-24 2020-04-30 California Institute Of Technology Near-infrared heptamethine dyes for generation of singlet oxygen
WO2020086697A1 (en) * 2018-10-24 2020-04-30 California Institute Of Technology Treatment of myopia and other ocular conditions using singlet oxygen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102645A (en) 1992-07-26 1998-02-22 Yeda Res & Dev Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
IL133253A0 (en) * 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
RU2201219C2 (ru) * 2001-04-24 2003-03-27 Макаров Константин Алексеевич Фармакологическая композиция пролонгированного действия
CA2462508A1 (en) * 2001-10-03 2003-04-10 Miravant Pharmaceuticals, Inc. Photosensitizing carbamate derivatives
IL152900A0 (en) 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
EP1753457B8 (en) * 2004-06-07 2016-09-21 Yeda Research And Development Co., Ltd. Cationic bacteriochlorophyll derivatives and uses thereof
RU2450018C2 (ru) * 2006-08-23 2012-05-10 Йеда Рисерч Энд Диверлопмент Ко. Лтд Конъюгаты rgd-пептидов и фотосенсибилизаторов порфирина или (бактерио)хлорофилла и их применение
JP5559540B2 (ja) 2006-10-24 2014-07-23 カリフォルニア・インスティテュート・オブ・テクノロジー 体組織の機械的および/または化学的性質に影響を及ぼすための光化学療法
RU2404768C1 (ru) * 2009-10-28 2010-11-27 Федеральное агентство по науке и инновациям Глазные капли
WO2011099602A1 (ja) * 2010-02-12 2011-08-18 学校法人日本大学 ポルフィリン誘導体および放射線力学療法におけるその使用

Also Published As

Publication number Publication date
KR20140088514A (ko) 2014-07-10
CN103930108A (zh) 2014-07-16
ES2856698T3 (es) 2021-09-28
HK1199412A1 (en) 2015-07-03
CN103930108B (zh) 2017-05-24
AU2012298156B2 (en) 2017-08-17
BR112014004306A2 (pt) 2017-03-28
MX360683B (es) 2018-11-13
WO2013027222A1 (en) 2013-02-28
AU2012298156A1 (en) 2014-04-10
RU2632439C2 (ru) 2017-10-04
HUE053321T2 (hu) 2021-06-28
KR101962991B1 (ko) 2019-03-27
US20210330792A1 (en) 2021-10-28
PT2747763T (pt) 2021-02-22
US11058772B2 (en) 2021-07-13
JP6215203B2 (ja) 2017-10-18
US20160354468A1 (en) 2016-12-08
MX2014002107A (es) 2015-04-16
US20140378888A1 (en) 2014-12-25
JP2014524465A (ja) 2014-09-22
ZA201402056B (en) 2015-11-25
CA2846011A1 (en) 2013-02-28
CA2846011C (en) 2019-10-15
DK2747763T3 (da) 2021-03-29
PE20141183A1 (es) 2014-10-05
US9452172B2 (en) 2016-09-27
US20190231874A1 (en) 2019-08-01
RU2014110784A (ru) 2015-09-27
EP2747763B1 (en) 2020-12-30
CL2014000432A1 (es) 2014-11-28
EP2747763A1 (en) 2014-07-02

Similar Documents

Publication Publication Date Title
IN2014CN02153A (pt)
MX347226B (es) Tratamiento de enfermedad ocular.
BR112017024531A2 (pt) lentes intraoculares ajustáveis por luz usando nanopartículas de conversão ascendente e luz do infravermelho próximo (nir)
HK1246646A1 (zh) 用於治療糖尿病性視網膜病及其他眼科疾病的方法
IL227412A (en) Administration of cross-materials to corne by iontophoresis for the treatment of keratoconus and ophthalmic preparations for this purpose
MY175318A (en) Androgen composition for treating an opthalmic condition
EA201301277A1 (ru) Композиции и способы лечения заболеваний сетчатки
MX361858B (es) Formulación oftálmica de lípido polioxilo o de ácido graso polioxilo y tratamiento de padecimientos oculares.
NZ704247A (en) Compositions and treatment for eye diseases and disorders
EA201490721A1 (ru) Лекарственное средство для лечения заболеваний передней камеры глаза, включающее ребамипид и агент, удерживающий слезы
WO2012080497A3 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
UA113627C2 (xx) Кристалічна форма циклоспорину a, фармацевтична композиція та спосіб лікування
NZ704178A (en) Difluorolactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
TR201900863T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması.
EA201490845A1 (ru) Улучшенная сшивающая композиция, доставляемая способом ионтофореза, пригодная для лечения кератоконуса
UY34843A (es) Tratamiento de enfermedades inflamatorias oculares usando laquinimod
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
WO2014003850A3 (en) Methods for treatment of ocular diseases
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
IL231052B (en) Bacteriochlorophyll photosensitizers for the treatment of eye diseases and disorders
UA38111U (ru) Способ предоперационной подготовки пациентов с миопией высокой степени к факоэмульсификации хрусталика с вживлением интраокулярной линзы
RU2013125864A (ru) Способ лечения прогрессирующей миопии высокой степени
RU2011150950A (ru) Способ комплексного лечения рефракционной амблиопии больных миопией высокой степени